The Efficacy and Safety of Chinese Medicine Fufang Zhenzhu Tiaozhi Capsule (FTZ) in the Treatment of Diabetic Coronary Heart Disease: Study Protocol for Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial
| Autor: | Shenghua Piao, Lexun Wang, Leyu Li, Jiao Guo, Lei Xiang, Qing Zhu, Wanxing Zhou, Huilin Li, Weixun Feng, Xiao Gong, Aisheng Wei, Xianglu Rong |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Acute coronary syndrome type 2 diabetes mellitus medicine.medical_treatment 030209 endocrinology & metabolism Traditional Chinese medicine 030204 cardiovascular system & hematology Revascularization Placebo 03 medical and health sciences Study Protocol traditional Chinese medicine 0302 clinical medicine Diabetes mellitus Internal medicine Internal Medicine Medicine Adverse effect Targets and Therapy [Diabetes Metabolic Syndrome and Obesity] Pharmacology business.industry clinical study medicine.disease Clinical trial Heart failure business |
| Zdroj: | Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy |
| ISSN: | 1178-7007 |
| Popis: | Lexun Wang,1 Lei Xiang,1,2 Shenghua Piao,1 Xiao Gong,3 Wanxing Zhou,4 Weixun Feng,5 Huilin Li,6 Leyu Li,7 Aisheng Wei,8 Qing Zhu,1 Xianglu Rong,1 Jiao Guo1,2 1Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine; Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China; Institute of Chinese Medicine, Guangdong Pharmaceutical University; Guangdong TCM Key Laboratory for Metabolic Diseases, Guangzhou, People’s Republic of China; 2The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People’s Republic of China; 3School of Public Health, Guangdong Pharmaceutical University, Guangzhou, People’s Republic of China; 4Department of Internal Cardiology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People’s Republic of China; 5Famous Doctor’s Studio, Qingyuan Hospital of Traditional Chinese Medicine, Qingyuan, People’s Republic of China; 6Department of Endocrinology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, People’s Republic of China; 7Department of Endocrinology, Zhongshan Hospital of Traditional Chinese Medicine, Zhongshan, People’s Republic of China; 8Department of Endocrinology, Foshan Hospital of Traditional Chinese Medicine, Foshan, People’s Republic of ChinaCorrespondence: Jiao GuoGuangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine; Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China; Institute of Chinese Medicine, Guangdong Pharmaceutical University; Guangdong TCM Key Laboratory for Metabolic Diseases, Guangzhou, People’s Republic of ChinaTel +86-02-39352818Fax +86-02-39352607Email gyguoyz@163.comBackground: Diabetic coronary heart disease (DCHD), the main macrovascular complication of type 2 diabetes mellitus (T2DM), is greatly harmful to T2DM patients. Traditional Chinese medicine (TCM) is an alternative and effective therapy to delay the development of macrovascular diseases, but the existing evidence of its efï¬cacy and safety is insufï¬cient. The aim of this multicenter, randomized, double-blind, placebo-controlled trial is to evaluate the efï¬cacy and safety of Chinese Medicine Fufang Zhenzhu Tiaozhi capsule (FTZ) in treating DCHD.Patients and Methods: This study includes a 2-week run-in, 52-week treatment, and 52-week post-treatment follow-up. A total of 160 participants will be recruited and randomized into two groups. The treatment group will receive FTZ and basic treatment, while the control group will receive the placebo and basic treatment. The primary outcome is the combined outcome including the major adverse cardiovascular events, coronary restenosis, and unplanned revascularization. The combined secondary outcomes include all-cause mortality, acute coronary syndrome, ischemic stroke, heart failure, unplanned re-hospitalization mainly caused by acute complications of diabetes, other thromboembolic events, and TCM symptom indicators. The safety outcomes and adverse events will also be evaluated in this trial.Discussion: This trial evaluates the clinical effectiveness and safety of FTZ in patients with DCHD. The results are important to further explore the effectiveness of the comprehensive strategy “Tiao Gan Qi Shu Hua Zhuo” (modulating Gan, trigging key metabolic system to resolve pathogenic factors such as phlegm retention and dampness) in the prevention and control of glucolipid metabolic disorders (GLMD) including DCHD and T2DM. On the other hand, this study is the ï¬rst trial of FTZ to observe cardiovascular outcomes through long-term follow-up after treatment of DCHD, which is of great value.Trial Registration: This trial was registered in the Chinese Clinical Trial Registry on April 07, 2019 (No. ChiCTR1900022345).Keywords: type 2 diabetes mellitus, traditional Chinese medicine, clinical study |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|